FDA Clearance Tracker · P080025-S049
INTERSTIM THERAPY FOR BOWEL CONTROL
Last checked: Nov 20, 2026Latest source record: Apr 15, 2014 (this decision)Source: openFDAMethods & limitations
Decided
Apr 15, 2014
Approved
Time to decision
404 days
Received Mar 7, 2013. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P080025-S049
- Device name
- INTERSTIM THERAPY FOR BOWEL CONTROL
- Applicant
- Medtronic Neuromodulation
- Applicant location
- Minneapolis, MN
- Received
- Mar 7, 2013
- Decided
- Apr 15, 2014
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - PAS
- Original approval
- P080025
Device type
- Device class
- Class III
- Regulation
- 21 CFR 876.5270
FDA's approval statement
As written in FDA's record.
APPROVAL FOR LABELING UPDATES TO INCORPORATE THE LONG-TERM DATA FROM THE FECAL INCONTINENCE POST-APPROVAL STUDY INTO THE INTERSTIM® THERAPY LABELING.
Source documents
Other decisions for Medtronic Neuromodulation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P240011 · Decided Sep 18, 2025 · 532 days after receipt
Device type: Stimulator, tibial, electrical, implantable, for urinary incontinence (QPT) · GI, Urology & Nephrology
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.